Informed Design

To inform the design of our platform, we conducted extensive research in the areas of malarial diagnosis, infectious diseases as well as policy surrounding diagnostic test internationally. We also reached out to many professionals working in the area of infectious diseases. We were able to speak with and interview:

• Dr. Lisa Allen Scott – PhD in Population and Public Health
• Dr. Allen Scott conducts research in Tanzania monitoring malaria rates in a small village. Her research found that malaria was nowhere near as widespread as previously believed.
• Dr. Abebe Bayih - PhD working with novel Anti-Malarials
• Dr. Bayih is an expert in the field of infectious diseases. Currently he is testing novel anti-malarial drugs in animals.
• Dr. Mofoluwaso Abolarin
• Dr. Abolarin worked as a surgeon in Nigeria for 10 years before relocating to Canada where he now serves as a family medical physician.

Each of these professionals provided insight into different areas of the project. They helped us to better understand the needs in the areas we would be targeting, as well as helping us to recognize potential obstacles.

In addition, we reached out to some friends of one our team members who previously lived in Kikaaya, Uganda. We connected with Derrick Luwaga who runs a non-profit organization (KACCAD) and medical clinic in a rural village. Derrick was able to speak with both the technicians and the physicians who work within the lab conducting malarial diagnosis. He sent us videos of the interviews he conducted, the process involved as well as documenting the available technology and resources. This was an amazing insight to have to guide our project, and to even better understand the needs of the end-user.

With all of this in mind we determined that our diagnostic tool would need to have several characteristics:

• Robust – able to withstand transport as well as harsh environmental conditions.
To make our device as robust as possible, we have used B. subtilis spores. These spores can withstand extreme heat and cold before their rehydration, and provide us with the necessary shelf life required by the World Health Organization.
• Affordable – our system must be attainable by our end user.
Although no current multiplexed standard exists, we have used the pricing suggested by the WHO for an HIV assay, which is a final device cost of no more than $10USD. Our consultation with FIND helped us realize the number of taxes that will be applied to our device, essentially doubling its original cost. For this reason we seek a final device price of no more than $5 per device.
• Adaptable – different geographic regions are faced with different ailments. The ability to customize our tool is key.
By simply changing the target sequence within our B. subtilis strain we are able to target different pathogens that might plague different geographical regions. This device could easily have different versions based on geography.
• Easy to Use – Not all clinics have trained technicians, in addition the detection system must be able to overcome language barriers by having clear, visible readouts.
Our device overcomes language barriers by displaying only colorimetric results. These results are clear and defined, leaving little room for misinterpretation.